Kaj pomeni »Počisti«?
Žival ne nosi mutacije. To ne bo razvilo bolezni in ga ne bo posredoval naprej.
pes Polinevropatija aljaškega malamuta (AMPN)
Alaskan Malamute Polyneuropathy (AMPN) is a genetic disorder that affects the nervous system of Alaskan Malamutes. A DNA test for AMPN can help dog owners identify whether their pets are carriers of this condition, which may lead to debilitating symptoms such as muscle weakness and impaired coordination. Early detection through DNA testing is crucial for managing the health of affected dogs, allowing for better care and informed breeding decisions. By knowing your dog's genetic status, you can take proactive steps to ensure a healthier life for your Alaskan Malamute. Don't wait—consider a DNA test today to safeguard your furry friend against AMPN. Protect your dog's well-being with this simple yet essential genetic screening.
Okrajšava: AMPN
Analizirana mutacija: NDRG1 c.293G>T
dedovanje: Avtosomno recesivno
akronim
AMPN
Opazovana frekvenca
Klinična resnost
Klinična klasifikacija
Nevrološke bolezni
Analizirana mutacija
NDRG1 c.293G>T
p.(G98V)
p.(G98V)
Način dedovanja
Avtosomno recesivno
Povzetek testa:
Alaskan Malamute Polyneuropathy (AMPN) is a genetic condition affecting the nervous system of Alaskan Malamutes. DNA testing for AMPN helps identify carriers and affected dogs, allowing breeders to make informed decisions to reduce the prevalence of this disorder. Symptoms may include muscle weakness and coordination issues, impacting the dog's quality of life. Early detection through genetic testing can aid in managing the condition effectively. Responsible breeding practices can help ensure healthier future generations of this beloved breed.
Na voljo iz paketa: Basic
Ta DNK test je vključen od našega paketa Basic — in je tudi del paketov Basic, Standard, Advanced, Complete.
Oglejte si pakete testov DNK →Izberite paket, ki najbolje ustreza vaši vzrejni ali zdravstveni strategiji vaših živali.
Understanding Alaskan Malamute Polyneuropathy (AMPN)
Alaskan Malamute Polyneuropathy (AMPN) is a hereditary neurological disorder that primarily affects Alaskan Malamutes, leading to a range of debilitating symptoms. This condition is characterized by the degeneration of peripheral nerves, which can result in significant mobility issues and impairments in the dog's overall quality of life.
Symptoms of AMPN
Dogs affected by AMPN may exhibit a variety of symptoms, which can vary in severity. Common signs include muscle weakness, difficulty in walking or running, and a noticeable decrease in coordination. As the disease progresses, affected dogs may develop tremors, a wobbly gait, and muscle atrophy. These symptoms often manifest between the ages of 6 months and 2 years, although the onset can vary.
Genetic Basis of AMPN
The condition is caused by a genetic mutation that affects the structure and function of nerve fibers. This mutation can be identified through a DNA test, which helps in diagnosing the condition before clinical signs become apparent. Understanding the genetic basis of AMPN is crucial for breeders and pet owners, as it aids in making informed decisions regarding breeding practices and the management of affected dogs.
Pomen testiranja DNK
DNA testing for AMPN plays a vital role in the early detection and management of the disease. By identifying carriers of the genetic mutation, breeders can take steps to avoid mating affected dogs, thereby reducing the incidence of the disorder in future generations. Moreover, knowing a dog’s genetic status can assist owners in making informed decisions about their pet’s care and potential lifestyle adjustments.
Managing AMPN
While there is currently no cure for AMPN, management strategies can significantly improve the quality of life for affected dogs. These may include physical therapy, pain management, and modifications to the dog's environment to accommodate mobility challenges. Regular veterinary check-ups are essential to monitor the condition and adjust treatment plans as needed.
Zaključek
Alaskan Malamute Polyneuropathy is a serious genetic condition that can severely impact the health and well-being of affected dogs. Through DNA testing, owners and breeders can take proactive steps in managing this disorder, ensuring that future generations of Alaskan Malamutes are healthier and less prone to AMPN. Understanding the implications of this condition is crucial for responsible breeding and compassionate care of affected dogs.
Pasma, priznana za test: Polinevropatija aljaškega malamuta (AMPN)
- Alaskan Malamute
🧬 Interpretation of genotypes AMPN
Genotip
Stanje
🟡 N/N
Brez prevoznika – brez tveganja
🟡 N/AMPN
Prevoznik - brez tveganja
❌ AMPN/AMPN
Prizadeti – ogroženi
Pogosta vprašanja: razumevanje interpretacije
Je "prevoznik" resen?
Ne. Žival je na splošno zdrava, vendar lahko prenese mutacijo na svojo potomci.
Kaj pa, če je žival "prizadeta"?
Nosi dve mutirani kopiji. Klinični znaki so pričakovani glede na bolezen. Ne sme se vzrejati.
Zakaj obstajajo razlike med moškim in žensko?
Nekatere bolezni so povezane s spolom, zato se njihov izraz razlikuje glede na spol živali.
Napoved potomcev
N/N (neprevoznik)
N/AMPN (Nosilec)
AMPN/AMPN (Prizadeti)
Pogosta vprašanja o testu DNK
Kaj ugotovi ta DNK test?
This DNA test detects the mutation associated with Alaskan Malamute Polyneuropathy (AMPN) in order to identify clear, carrier, or at-risk animals.
Zakaj testirati plemensko žival?
Testiranje DNK pomaga rejcem pri načrtovanju varnejših parjenj in zmanjšanju tveganja prenosa mutacije na potomce.
Kakšen je način dedovanja tega testa?
Način dedovanja, poročan za ta test, je avtosomno recesivno.
Katero mutacijo analiziramo v tem testu?
This test analyses the mutation NDRG1 c.293G>T.
Ali je žival prenašalka nujno prizadeta?
Ni nujno. Razlaga je odvisna od vzorca dedovanja in nastalega genotipa.
Reference
Bruun Camilla S, Jäderlund Karin H, Berendt Mette, Jensen Kristine B, Spodsberg Eva H, Gredal Hanne, Shelton G Diane, Mickelson James R, Minor Katie M, Lohi Hannes, Bjerkås Inge, Stigen Oyvind, Espenes Arild, Rohdin Cecilia, Edlund Rebecca, Ohlsson Jennie, Cizinauskas Sigitas, Leifsson Páll S, Drögemüller Cord, Moe Lars, Cirera Susanna, Fredholm Merete. A Gly98Val mutation in the N-Myc downstream regulated gene 1 (NDRG1) in Alaskan Malamutes with polyneuropathy. PLoS One. 2013;8(2):e54547. doi: 10.1371/journal.pone.0054547. Epub 2013 Feb 5.